CEL-SCI Developing Immune-Based Treatment Against Swine And Other H1N1 Flu Viruses Using Proprietary L.E.A.P.S. Technology

CEL-SCI Corporation (NYSE AMEX: CVM) announced that it is developing an immune-based treatment for the “swine flu and related H1N1″ flu viruses, utilizing its proprietary L.E.A.P.S.(TM) (Ligand Epitope Antigen Presentation System) vaccine technology. The Company plans to utilize the expertise and knowledge it has gained from developing protective and therapeutic vaccines utilizing L.E.A.P.S. to develop a therapeutic treatment based upon the technology for people infected with the swine and H1N1 flu viruses. CEL-SCI has already commenced pre-clinical testing.

Previously, CEL-SCI announced that its CEL-1000 peptide, which is derived from the L.E.A.P.S. technology, showed adjuvant activity when used with a peptide based malaria vaccine and a DNA based malaria vaccine in animal challenge studies as part of a Cooperative Research arrangement with the Naval Medical Research Center, Silver Spring, MD. In both cases, the addition of CEL-1000 to the vaccines resulted in significant increases in the protection of the animals. In addition, several different L.E.A.P.S. conjugates induced protection and/or improvement in diseases as diverse as rheumatoid arthritis, malaria, TB and herpes simplex viruses. This shows that the L.E.A.P.S. technology can be successfully applied to many different diseases and these results further suggest that L.E.A.P.S. has the potential to be used either alone as a therapy or as an adjuvant to vaccines under development for the treatment of H1N1 related flu viruses. Adjuvants are designed to improve the effectiveness of vaccines.

“We believe that our L.E.A.P.S. technology platform offers strong potential to address the current swine and H1N1 flu viruses,” said Dr. Daniel Zimmerman of CEL-SCI, the inventor of the technology. “With the swine flu currently creating major global health problems despite it occurring outside of the traditional windows for the flu, we are working diligently to provide a solution as it is expected that the disease may become even more virulent later this year during the traditional flu season.”

Read more….